NIVESTYM

This brand name is authorized in United States. It is also authorized in Canada.

Active ingredients

The drug NIVESTYM contains one active pharmaceutical ingredient (API):

1	Filgrastim UNII PVI5M0M1GW - FILGRASTIM
	Filgrastim causes marked increases in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes.
	Read more about Filgrastim

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
NIVESTYM Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L03AA02	Filgrastim	L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AA Colony stimulating factors
Discover more medicines within L03AA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02485575, 02485583, 02485591, 02485656
US	FDA, National Drug Code	0069-0291, 0069-0292, 0069-0293, 0069-0294